Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viveve Medical's gross profit for the
three
months ended in Sep. 2022 was $0.55 Mil. Viveve Medical's gross profit for the trailing twelve months (TTM) ended in Sep. 2022 was $1.12 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Viveve Medical's gross profit for the
three
months ended in Sep. 2022 was $0.55 Mil. Viveve Medical's Revenue for the
three
months ended in Sep. 2022 was $1.68 Mil. Therefore, Viveve Medical's Gross Margin % for the quarter that ended in Sep. 2022 was 32.42%.
Viveve Medical had a gross margin of 32.42% for the quarter that ended in Sep. 2022 => Competition eroding margins
Viveve Medical (OTCPK:VIVE) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Viveve Medical had a gross margin of 32.42% for the quarter that ended in Sep. 2022 => Competition eroding margins
Viveve Medical Gross Profit Related Terms
Viveve Medical Gross Profit Historical Data
* Premium members only.
The historical data trend for Viveve Medical's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Viveve Medical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viveve Medical Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viveve Medical's Gross Profit distribution charts can be found below:
* The bar in red indicates where Viveve Medical's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.12 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Viveve Medical (VIVE) has a Gross Profit of $1.12 Mil as of Sep. 2022. Gross Profit equals net sales less total cost of goods sold. View historical data on Viveve Medical and its competitors.
Is Viveve Medical's Gross Profit too high?
Viveve Medical's current Gross Profit is $1.12 Mil. Overall, Viveve Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Viveve Medical's Gross Profit compare to NNMX and LHDXQ?
Viveve Medical's Gross Profit of $1.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Viveve Medical and its competitors. Viveve Medical's current Gross Profit is $1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viveve Medical stock overvalued right now?
Viveve Medical (VIVE) has a current Gross Profit of $1.12 Mil. The current Gross Profit is $1.12 Mil. Viveve Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Viveve Medical (VIVE), the current Gross Profit is $1.12 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.
12GF Score
Get the complete analysis for VIVE
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIVE has been successfully added to your 
